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ABSTRACT
The regulation of gene expression by estrogen
receptor-a (ERa) requires the coordinated and tem-
poral recruitment of diverse sets of transcriptional
co-regulator complexes, which mediate nucleosome
remodelling and histone modification. Using ERa as
bait in a yeast two-hybrid screen, we have identified a
novel ERa-interacting protein, ZNF366, which is a
potent corepressor of ERa activity. The interaction
between ZNF366 and ERa has been confirmed
in vitro and in vivo, and is mediated by the zinc
finger domains of the two proteins. Further, we show
that ZNF366 acts as a corepressor by interacting with
other known ERa corepressors, namely RIP140 and
CtBP, to inhibit expression of estrogen-responsive
genes in vivo. Together, our results indicate that
ZNF366 may play an important role in regulating the
expression of genes in response to estrogen.
INTRODUCTION
Estrogens play diverse roles in the body, most notably in the
development and maintenance of the female and the male,
reproductive systems and secondary sexual characteristics
(1). Estrogens also play a central role in promoting breast
cancer growth (2), as well as being implicated in uterine
and ovarian cancers (3,4), and are also implicated in the
physiology of the brain, bone and the cardiovascular system,
as evidenced by the increased risk of cardiovascular disease
and osteoporosis engendered by the decline in estrogen levels
during menopause (1).
Estrogen action is mediated by two highly related
estrogen receptors (ERa and ERb), which are members of
the ligand-activated nuclear receptor (NR) superfamily of
transcription factors (5,6). NRs are characterized by a DNA
binding domain (DBD), comprised of two zinc fingers,
which mediate receptor dimerization and binding to specific
response elements in the promoters of target genes. Binding
of the ligand to the ligand binding domain (LBD), located
C-terminal to the DBD, results in a conformational change
in the LBD and activation of the intrinsic transcription activa-
tion function AF2, which facilitates the recruitment of
transcriptional coactivators (7,8). Transcription activation
requires cooperation of AF2 with a region N-terminal to the
DBD that encodes transcription activation function AF1,
which is often, as in the case of ERa and ERb, regulated
by phosphorylation at specific serine residues (9–11).
The liganded estrogen receptors regulate gene expression
by direct binding to DNA at estrogen response elements in
target genes, resulting in the recruitment of diverse transcrip-
tional coregulators, including the SWI–SNF complexes that
remodel chromatin to alter nucleosomal organization in an
ATP-dependent manner (12), the p160 family of coactivators
(SRC1/NCo-A1, TIF-2/GRIP1 and AIB1/pCIP/ACTR/
RAC3/TRAM1) and TRAP/DRIP complexes. (13–15). The
p160 coactivators facilitate the recruitment of other proteins,
including CBP, its homologue p300 and p/CAF, which pos-
sess intrinsic histone acetyltransferase activity, as well as
histone methyltransferases CARM1 and PRMT1 that methy-
late arginine residues in histone tails (16,17). The thyroid
receptor–associated protein (TRAP) complex, similar to or
identical with the vitamin D3 receptor–interacting protein
(DRIP) complex, which is also similar in many respects to
the Mediator complex acts to bridge RNA polymerase II
with basal transcription factors and transcription activators.
These and other coregulators are recruited to gene promoters
in a sequential/ordered manner, resulting in cycles of
chromatin remodelling and modification that facilitate
transcription (13,15,18).
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The ERa LBD is composed of 12 a-helices packed in three
layers, with a central hydrophobic pocket that accommodates
the ligand (7). Helix 12, together with helices 3, 4 and 5, form
a coactivator-binding groove. Most coactivators recruited by
agonist-bound ERa contain LXXLL motifs, which form a
two-turn amphipathic a-helix that fits into the coactivator-
binding groove in the ERa LBD (8,19–22). In addition to
the well-characterized recruitment of coactivators to the
LBD/AF2, coactivator interaction with AF1 of estrogen
receptors has also been described, the interaction being
influenced by the phosphorylation status of the receptor in
some cases (23–25).
When unliganded, some DNA-bound NR recruit the core-
pressors NCoR and SMRT and associated protein complexes
implicated in transcriptional repression and histone deacety-
lation, these complexes being dissociated upon ligand binding
(13–15,26). NCoR/SMRT bind to NR through CoRNR boxes,
LXXI/HIXXXL/I motifs, that form a more extended a-helix
than the LXXLL motifs, with helix 12 in the LBD being
displaced from the conformation it occupies in the agonist-
bound LBD (27,28). NCoR/SMRT is also recruited by
antagonist-bound ERa to inhibit gene expression (29–31).
In addition to stimulating gene expression, estrogen-bound
ER represses the expression of many genes. Indeed, gene pro-
filing studies show that the down-regulation of gene expres-
sion is a significant feature of the response to estrogen in
the ERa-positive, estrogen-responsive MCF7 breast cancer
cell line (32). This is likely to involve transcriptional
corepressors, such as LCoR and RIP140, which can be
recruited to the agonist-bound ERa via LXXLL motifs
(20,33,34). Repression by LCoR and RIP140 occurs through
HDAC-dependent and -independent mechanisms and involves
the recruitment of HDACs and the C-terminal binding protein
(CtBP) corepressor (34–39). CtBP, originally identified based
on its interaction with the C-terminal end of adenovirus E1A
via the sequence PLDLS, is highly conserved in higher
eukaryotes and plays a critical role in development (40,41).
Other transcription factors also interact with CtBP1, and the
highly related CtBP2, through PXDLS motifs. Although, the
mechanisms by which CtBP acts as a corepressor have not
been fully defined, a recent study has identified CtBP com-
plexes that contain HDACs and histone lysine methyltrans-
ferases (42).
The ERa DBD participates in the recruitment of transcrip-
tional co-regulator proteins. These include the coactivator
XBP-1 (43), which modulates ERa signalling both in
the absence and presence of estrogen, the signal transducer
and activator of transcription-5 (STAT 5) (44) and the
corepressor TAF-Ib that has been shown to decrease ERa
acetylation (45). Here, we report that ZNF366, which encodes
an evolutionarily conserved zinc finger protein, interacts with
the ERa DBD. We also show that ZNF366 represses ERa
activity through association with RIP140, CtBP and histone
deacetylases.
MATERIALS AND METHODS
Plasmids
The mammalian expression plasmids and reporter genes
have previously been described (37,46–49). Site-directed
mutagenesis was used to introduce an EcoRI site 50 to the
GAL4 translation initiation site in the pBridge yeast expres-
sion plasmid (BD Biosciences, UK), enabling cDNA
sequences encoding ERa and ERaDLBD to be cloned at
this position following removal of the GAL4 sequences
encoded between the introduced EcoRI site and the multiple
cloning site in pBridge. The pACTII-ZNF366 clone isolated
from the yeast 2-hybrid screening encodes sequences corre-
sponding to 439–2761 bp of the ZNF366 mRNA sequence
with the accession number NM_152625 in the NCBI database
(www.ncbi.nlm.nih.gov). The full-length ZNF366 open read-
ing frame was reconstituted from the pACTII-ZNF366 clone
and IMAGE EST clone 5204702 (accession no. BI770486),
to generate pCMVSPORT6-ZNF366 in which ZNF366 is
C-terminally FLAG-tagged. ZNF366 deletion and point
mutants were generated by site-directed mutagenesis accord-
ing to manufacturer’s protocols (Stratagene, UK).
Yeast 2-hybrid screening
PL1a (MATa ura3-D1 his3-D200 leu2-D1 trp1::ERE)1-URA3
yeast strain (50) was transformed with pBridge(Mod)-
ERa-DLBD, together with a human placental cDNA expres-
sion library (BD Biosciences, UK), using the Alkali-Cation
yeast transformation kit (BIO 101 systems, UK). Following
transformation, the cells were plated on 15 cm trp leu
ura plates. Positive clones arising from the screening of
2 · 104 transformants were re-screened and plasmid
DNAs were isolated using the lyticase method from BD
Biosciences, UK. Plasmids from positive clones were re-
transformed, together with pBridge(Mod)-ERa-DLBD or
pBridge(Mod)-ERa and interactions confirmed by growth
on trp leu ura plates.
Northern blotting
Multiple tissue northern blots MTN I and MTN II (BD
Biosciences, Europe) were probed following 32P-labelling
of the ZNF366 cDNA isolated from the pACTII-ZNF366
clone, as described (51).
Protein expression, purification and glutathione
S-transferase (GST)-based interaction assay
In vitro transcription/translations were performed using TNT
rabbit reticulocyte lysates (Promega, UK), in the presence of
[35S]-labelled methionine. GST proteins were induced and
Escherichia coli lysates prepared as described previously
(33). For pulldowns, GST fusion proteins were purified by
affinity chromatography on glutathione-agarose beads and
retained as 50% slurry in 20 mM HEPES (pH 7.6),
100 mM KCl, 1 mM EDTA, 1 mM DTT, 20% glycerol,
supplemented with protease inhibitors. A total of 100 ml vol-
umes of glutathione-agarose bead slurry loaded with 10 mg of
GST fusion proteins were then used directly in binding assays
with 10 ml of radiolabelled in vitro translation reactions and
890 ml of low salt buffer [50 mM HEPES (pH 7.6),
250 mM NaCl, 0.5% NP-40, 5 mM EDTA, 0.1% BSA,
0.5 mM DTT, 0.005% SDS and protease inhibitors]. Follow-
ing 1 h incubation at room temperature, the beads were
washed twice with low salt buffer and twice with high-salt
buffer (low salt buffer, but with 1 M NaCl). Samples were
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boiled for 10 min in 80 ml of Laemmli buffer and fractionated
by SDS–PAGE. Gels were dried and autoradiographed.
Reporter gene assays
COS-1 cells were maintained in DMEM, supplemented with
5% fetal calf serum (FCS). For transient transfection, cells
were seeded in 24-well plates in DMEM lacking phenol red
and supplemented with 5% dextran-coated charcoal-stripped
FCS (DSS). Following seeding for 24 h, the cells were
transfected using Fugene 6 (Roche Diagnostics, UK), with
100 ng of luciferase reporter gene and amounts of expression
plasmids as indicated in the figure legends. E2 (10 nM),
4-hydroxytamoxifen (OHT; 100 nM) or ICI 182, 780 (ICI;
100 nM) were added as appropriate. Since the ligands were
prepared in ethanol, an equal volume of ethanol was added
to the no ligand controls. Luciferase activities were deter-
mined using the Dual-Glo Luciferase Assay kit (Promega,
UK). For the other reporter gene assays, cells were
maintained in DMEM, supplemented with 5% FCS and
transfections carried out as above.
Immunoprecipitations and immunoblotting
COS-1 cells were plated in 9 cm dishes in DMEM supple-
mented with 5% FCS 16 to 24 h prior to transfection. The
cells were transfected with 5 mg of the ZNF366-FLAG and
ERa expression plasmids using Lipofectamine 2000 (Invitro-
gen, UK). Following transfection for 48 h, the cells were
lysed in RIPA buffer [150 mM NaCl, 1% NP-40, 0.5%
deoxycholic acid, 0.1% SDS and 50 mM Tris–HCl
(pH 7.5)] containing protease inhibitors. Lysates (2 mg)
were immunoprecipitated (IP) using the M2 anti-FLAG
mouse monoclonal antibody (Sigma–Aldrich, UK), or using
an anti-ERa antibody (6F11; Novocastra, UK). Control IPs
was carried out using mouse IgG (Sigma–Aldrich, UK). IPs
were resolved by SDS–PAGE and immunoblotted using
horseradish peroxidase (HRP)-labelled HA antibody (Sigma–
Aldrich, UK) or using an anti-ERa rabbit polyclonal antibody
HC20 (Santa Cruz, UK). Co-IP of ZNF366-FLAG with CtBP
was carried out as above, except that a mouse monoclonal
CtBP antibody (sc-17759; Santa Cruz) was used for the IPs
and a rabbit polyclonal CtBP antibody (sc-11390; Santa
Cruz) was used for immunoblotting.
MCF7 cells cultured for 3 days in DMEM lacking phenol
red and supplemented with 5% DSS, were transfected with
1 mg of ZNF366-FLAG or vector control, using Fugene 6.
The media were replaced with media containing E2
(10 nM) or vehicle, 24 h following transfection and the
cells were harvested after a further 24 h. Immunoblotting
was performed using antibodies for cathepsin D (ab6313;
Abcam, UK), progesterone receptor (SC538; Santa Cruz
Biotechnologies, UK), FLAG-M2 and b-actin (ab6276;
Abcam, UK).
Immunofluorescence
COS-1 cells plated on glass coverslips placed in 24-well
plates in DMEM lacking phenol red and containing 5%
DSS, were transiently transfected with 50 ng of ZNF366-
FLAG and/or [ERa-DNLS (HE257G; (48)] using Fugene 6.
Five hours following transfection, culture media were
replaced by fresh media containing E2 (100 nM), OHT
(1 mM) or ICI 182, 780 (100 nM), or an equal volume of
vehicle (ethanol), as appropriate. 24 h later, cells were fixed
by the addition of 4% formaldehyde for 10 min at room
temperature, washed with phosphate-buffered saline (PBS)
and 0.1 M glycine was added for 10 min to neutralize the
formaldehyde. Following further washing with PBS, the
cells were permeabilized in 1% Triton/PBS for 5 min. After
washing with PBS, the cells were incubated at 37C for 1 h
with the 6F11 ERa antibody (1:50 dilution) and rabbit poly-
clonal FLAG antiserum (Santa Cruz Biotechnology, UK)
(1:350 dilution). The cells were washed and incubated
for 1 h at 37C with Alexa Fluor 488 goat anti-mouse
immunoglobulins (green) and Alexa Fluor 594 goat anti-
rabbit immunoglobulins (red) (1:3000 dilution). The cover-
slips were mounted on microscope slides using mountant
containing Dapi (Vector Laboratories, UK) and immunofluo-
rescence observed using a Zeiss LSM510 confocal
microscope.
Growth assays
MCF7 and MDA-MB-231 cells (2 · 105 cells per well) were
seeded in 6-well plates in DMEM lacking phenol red and
containing 5% DSS. After 48 h the cells were transfected
with 1 mg of ZNF366 or empty vector using Fugene 6. E2
(10 nM) was added after 24 h and cell numbers determined
using a haemocytometer after a further 48 h.
RNA interference and RT–PCR analysis
of gene expression
PE04 cells (2.5 · 105 cells) seeded in 6-well plates in RPMI
lacking phenol red and containing 5% DSS, were transfected
with double-stranded RNA oligonucleotides for ZNF366,
lamin A/C or a non-targeting siRNA (Ambion, UK), in
serum-free DMEM lacking phenol red, using Oligofectamine
(Invitrogen, UK), according to manufacturer’s protocols.
After 4 h the medium was changed to DMEM lacking
phenol red, supplemented with 5% DSS and containing E2
(10 nM), as appropriate. RNA was prepared after a further
24 h and RT–PCR carried out using primers with the
sequences: 50-GGACCAGCTTCAGTCACCTTTCCAGT-
GGTGGCC-30 and 50-GGGAGTAAAGCTGGTGCCTGG-
GGCACAGGTCACG-30 (GREB1), 50-CCCCATCCAGT-
ACAACTGCT-30 and 50-CTTCACGTCAGAGTGGACGA-
30 (ZNF366), 50-GCGTACGGCTCTCATCAACT-30 and 50-
GACACTGGAGGCAGAAGAGC-30 (Lamin A/C) and 50-
TCCCATCACCATCTTCCA-30 and 50-CATCACGCCACA-
GTTTCC-30 (GAPDH).
RESULTS
Identification of ZNF366
We utilized yeast strain PL1a, encoding an integrated
estrogen-responsive URA3 gene (50), for screening of a
human placental cDNA expression library for proteins that
interact with an ERa deletion mutant lacking the LBD
(ERa-DLBD). Screening of 2 · 104 transformants yielded
24 positive clones. One of these encoded the C-terminal
portion of ZNF366, described previously based on gene
prediction of genomic DNA sequence of human chromosome
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5q13.2. Human ESTs were identified using the NCBI site
(http://www.ncbi.nlm.nih.gov/BLAST/) by carrying out a
BLAST search against the database of human ESTs, using
sequences derived from the yeast 2-hybrid clone. The exact
intron/exon structure of ZNF366 was established by complete
DNA sequencing of overlapping EST IMAGE clones with
GenBank accession nos BI523869, 5201353, BI770486 and
BE552137 to generate an mRNA sequence encoding a pre-
dicted polypeptide of 744 amino acids (Figure 1A), encoded
within 5 exons. Based on the homology with the Fugu fZF1
gene, this was subsequently confirmed by Gilligan et al. (52).
Homology searches identified genes in mouse, rat, dog,
chicken and Xenopus tropicalis, having very high amino
acid sequence homology (93% or greater) in the zinc finger
region and all of which encode 11 zinc fingers (Figure 1B).
Regions N- and C-terminal to the zinc fingers were also
well conserved, albeit less so than the zinc finger region.
Together, the high degree of sequence conservation indicates
that the identified vertebrate genes represent orthologues of
human ZNF366. Support for this idea is provided by
additional homology searches, which indicated that the
human gene most closely related to ZNF366 is ZNF710,
also encoding an 11 zinc finger protein, the zinc finger
regions of human ZNF366 and ZNF710 showing amino
acid sequence identity of 78%, considerably lower than the
identity between human and the putative ZNF366 homologue
in chicken or Xenopus. Moreover, no significant homology
was detectable between human ZNF366 and ZNF710 outside
the zinc finger region. All other human genes demonstrating
homology to human ZNF366 displayed amino acid sequence
identities no better than 39%, when the zinc finger region of
ZNF366 was used in the BLAST searching. Together with the
previous report demonstrating, based on very high (88%)
amino acid sequence homology in the zinc finger region, as
well as conservation of the chromosome location of human
ZNF366 and the Fugu fZF1 gene (52), these analyses indicate
that ZNF366 is highly conserved in vertebrate evolution.
Northern blotting of human tissue RNAs demonstrated that
ZNF366 is broadly expressed at varying levels in human
adult tissues, with highest expression in heart, placenta,
muscle and spleen, with possible alternative splice forms in
the liver and muscle (Figure 1C).
Interaction of ZNF366 with ER-a
To further confirm interaction between ERa and ZNF366,
whole cell lysates were prepared from COS-1 cells transiently
transfected with ERa and FLAG-tagged ZNF366, in the
presence of E2. IP with FLAG antibody, followed by
immunoblotting using the HC20 rabbit polyclonal ERa anti-
serum, showed that ERa interacts with ZNF366 (Figure 2A),
whilst IP of ERa co-immunoprecipitated ZNF366-FLAG
(Figure 2B), indicating that ERa and ZNF366 interact
in vivo.
As expected, PL1a cells co-transformed with
pBridge(Mod)-ERa-DLBD and pACTII-ZNF366 grew on
minimal medium lacking lacking uracil (Figure 2C). How-
ever, for full-length ERa, productive interaction, as assayed
by growth in the absence of uracil, was ligand-dependent,
requiring the addition of estrogen (17b-estradiol; E2) or an
anti-estrogen 4-hydroxytamoxifen (OHT).
In order to confirm the ligand requirement for the
interaction between ERa and/or ZNF366 in mammalian
cells, COS-1 cells were transfected with ERaDNLS,
which is excluded from the nucleus (48). ZNF366-FLAG
was exclusively localized to the nuclei (Figure 2D), whilst
Figure 1. The amino acid sequence and tissue distribution of human ZNF366.
(A) The deduced amino acid sequence of human ZNF366 is shown in the
single letter amino acid code, with the cysteine (C) and histidine (H) residues
of the 11 zinc fingers in ZNF366 highlighted, as are the conserved
phenylalanine (F) and leucine (L) residues. Potential CtBP binding motifs
and an LXXLL motif are underlined. (B) A schematic representation of
ZNF366 from different species is shown, together with the position of the
zinc fingers and the putative CtBP and LXXLL motifs, the sequences for
these motifs in human ZNF366 being shown. The numbers below the
representation of ZNF366 from each species refer to percentage amino acid
sequence homology relative to human ZNF366. The numbers to the right
refer to the predicted number of amino acids encoded by the ZNF366 genes
from different species. The region encoding 277–1053 amino acids was used
for alignment in the case of the chicken ZNF366. ZNF366 sequences used
here have GenBank accession nos NM_152625 (human), NM_001004149
(mouse), XM_226715 (rat), XP_544370 (dog) and XP_429153 (chicken).
The Xenopus tropicalis ZNF366 sequence was derived from the ENSEMBL
database, from sequences having the Gene ID ENSGALG00000015008.
(C) Northern blot of 2 mg of poly(A)+ RNA from the tissues indicated, probed
with ZNF366 cDNA. Size markers are shown on the right.
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ERaDNLS was always cytoplasmic in the presence of E2,
or in the presence of the anti-estrogens OHT or ICI 182, 780
(ICI), as well as in the absence of ligand, when expressed
alone (data not shown). In cells co-transfected with
ZNF366-FLAG and ERaDNLS, ERaDNLS re-localized
to the nucleus when E2, OHT or ICI were present, but not
in the absence of ligand, indicative of ligand-dependent inter-
action between the two proteins. These data further demon-
strate that ERaDNLS and ZNF366 interact in vivo and in
agreement with the yeast 2-hybrid data, show that the
in vivo interaction requires estrogen agonist or antagonist
binding by ERa.
In contrast, in vitro binding assays showed that ERa bound
to GST-ZNF366 in the absence of ligand, as well as in the
presence of E2 or anti-estrogens, although the interaction
appeared to be greater in the presence of E2 and ICI
(Figure 3C), which may suggest that the interaction between
ERa and ZNF366 in vivo is regulated by other factors (see
Discussion). ERa can be phosphorylated at serine 118 within
AF1, and substitution of this residue by alanine significantly
reduces ERa activity (53). Substitution of leucine-539 and
leucine-540 in the LBD also dramatically reduces ERa
activity, by preventing coactivator recruitment (54). Substitu-
tion of serine 118 or of leucine-539/540 did not inhibit
ZNF366 interaction with ERa, suggesting that AF1 and the
LBD/AF2 may not be involved in the interaction of
ZNF366 with ERa.
GST pulldowns were performed to delineate the regions of
ERa and ZNF366 required for their interaction. ERa deletion
mutants lacking AF1 (ERaDAF1) or the LBD
(ERaDLBD) interacted with ZNF366, as did the isolated
ERa DBD (Figure 3D), whereas the interaction with the
LBD was weak, suggesting that the ERa DBD is required
for interaction with ZNF366. GST fusion proteins encoding
the N- and C-terminal regions of ZNF366, ZNF366(9–251)
and ZNF366(558–744) respectively, did not interact with
ERa, indicating that the zinc finger region is required for
the interaction. Interestingly, this assay suggests that the
interaction requires independent binding to several zinc
fingers, since ZNF366(9–452) and ZNF366(455–744),
which do not overlap, both interacted with ERa.
ZNF366 is a corepressor for ERa
In reporter gene assays, co-transfection with increasing
amounts of ZNF366 showed a dose-dependent inhibition of
ERa activity (Figure 4A). ZNF366 repressed AF1 (ERa-
DLBD; Figure 4B) and AF2 (ERa-DAF1; Figure 4C), in
agreement with the GST pulldowns that indicate interaction
of ZNF366 with the ERa DBD. A trans-repression assay
was employed to see whether ZNF366 is a repressor and
encodes autonomous repression domain(s). For this, a
luciferase reporter gene under the control of LexA and
Gal4 binding sites upstream of an E1A TATA box was
used. As expected, LexA-VP16 stimulated reporter gene
expression (Figure 4D), with this activity being reduced in
a dose-dependent manner by the Gal4 DBD fused to the
NR corepressors RIP140 (Gal4-RIP140), as described
previously (37). ZNF366 similarly repressed reporter gene
activity in a dose-dependent manner, confirmative of its
activity as a transcriptional repressor.
Figure 2. Interaction of ZNF366 with ERa. (A and B) Lysates prepared from
COS-1 cells transiently transfected with ERa and ZNF366-FLAG were
immunoprecipitated with mouse IgG, or with ERa or FLAG antibodies. Input
represents 5% of the total volume of lysate used in the immunoprecipitations.
(C) Cultures of PL1a yeast cells transformed with pBridge(Mod),
pBridge(Mod)-ERa-DLBD or pBridge(Mod)-ERa, together with pACTII or
ZNF366 were spotted at various dilutions, as indicated. Yeast growth was
performed over 7 days at 30C, in the presence of 17b-estradiol (E2; 1 nM),
4-hydroxytamoxifen (OHT; 100 nM) or in the absence of ligand (no ligand),
on plates lacking tryptophan, leucine and uracil. (D) COS-1 cells transiently
transfected with ERaDNLS and/or FLAG-ZNF366 were visualized by
immunofluoresecent staining, as described in Materials and Methods. Dapi
was used to visualize nuclei. Estrogen (100 nM), OHT or ICI (100 nM) were
added as indicated.
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In order to address the potential activity of ZNF366
on ERa-regulated gene expression, we looked for human
cell lines in which the genes were co-expressed (data not
shown). The PE04 ovarian cancer cell line was found
to express both ERa (3) and ZNF366 (Figure 4E). Transfec-
tion with siRNA for ZNF366 resulted in down-regulation of
ZNF366 expression and concomitant increase in the
expression of the estrogen-responsive GREB1 and TERT
genes, indicating that ZNF366 is involved in the regulation
of estrogen-responsive gene expression in vivo.
ZNF366 interacts with CtBP in vitro and in vivo
Since ZNF366 can repress ligand-stimulated ERa activity,
we wondered whether it interacts with other corepressors
that are known to associate with ERa in a ligand-dependent
manner. Amongst these is RIP140 (33), which acts by recruit-
ing HDACs and C-terminal binding protein (CtBP) (37).
In GST pulldown assays, ZNF366 interacted with RIP140
1–415 and 753–1158 amino acids (Figure 5A), which encode
repression domains RD1 and RD4 (37). This interaction
appeared to require the C-terminal-most zinc fingers 8–11
of ZNF366 (Figure 5B).
Interestingly, ZNF366 also interacted with CtBP1
(Figure 5A), the interaction apparently requiring sequences
C-terminal to the zinc fingers (Figure 5B). Many proteins
interact with CtBP through sequence motifs having the
consensus sequence PXDLS, with a lysine residue two
amino acids C-terminal to the serine also often being
present (41). Two such motifs, 590-PFDLS(QK)-596 and
645-PEDLS(TK)-651 (Figure 1) are located within the region
of ZNF366 required for interaction with CtBP. Mutation of
the CtBP motifs by substituting the proline (P) and aspartic
acid (D) residues by alanines, prevented interaction between
ZNF366 and CtBP in GST pulldown assays (Figure 5C) and
in a mammalian two-hybrid assay (Figure 5D). Mutation
of M1 or the M2 motif reduced the interaction between
ZNF366 and CtBP1. In these assays, the N-terminal CtBP
motif (M1) appeared to be more important than the
C-terminal motif (M2).
In the trans-repression assay, mutation of the N-terminal-
most CtBP binding motif in ZNF366 (M1) partially relieved
the repression of LexA-VP16 (Figure 5E), whereas mutation
of the second motif (M2) did not significantly relieve
the repression and mutation of both motifs almost completely
abolished the repression by ZNF366. These findings
show that the interaction between ZNF366 and CtBP is
important for the repression activity of ZNF366, the interac-
tion being mediated by two CtBP-interaction motifs, with
both motifs being required for the interaction with CtBP,
although motif M1 may be more important than M2 for the
interaction.
Whole cell lysates prepared from COS-1 cells transiently
transfected with CtBP1 and FLAG-tagged ZNF366 immuno-
precipitated using a CtBP antibody resulted in co-IP of
FLAG-ZNF366 (Figure 5F). In the reciprocal experiment,
CtBP1 was co-immunoprecipitated with FLAG-ZNF366
(Figure 5G). CtBP1 was not co-immunoprecipitated with
ZNF366 in which the CtBP binding motifs were mutated.
Collectively these data demonstrate that ZNF366 interacts
in vitro and in vivo with CtBP1, the interaction being
mediated by two CtBP binding motifs. In agreement with
these findings substitution of the CtBP motifs in ZNF366
significantly reduced the repression of ERa activity by
ZNF366 (Figure 6A).
Gene repression by transcriptional corepressors, including
RIP140 and CtBP, frequently requires HDAC recruitment
and histone deacetylation. The HDAC inhibitor suberoy-
lanilide hydroxamic acid (SAHA) relieved the repression
of ERa activity by ZNF366 (Figure 6B), whilst GST pull-
downs showed that ZNF366 interacts with HDACs 1, 3 and
6 (Figure 6C), indicating that transcriptional repression by
Figure 3. In vitro interaction between ER and ZNF366. (A and B) Schematic
representations of ERa, ZNF366 and deletion mutants are shown. All
N-terminal ZNF366 fusion proteins started at amino acid 9, thereby avoiding
potential internal translation start sites. (C and D) GST binding assays were
carried out by incubation of 35S-labelled ERa or mutants with GST or
GST–ZNF366 fusion proteins, in the absence of ligand (NL) or in the
presence of 100 nM E2, OHT or ICI. E2 was present throughout in part (D).
Input lanes represent 20% of the total volume of the in vitro translation
reaction used in the binding assay.
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ZNF366 is mediated, at least in part through histone
deacetylation.
ZNF366 represses the expression of estrogen-responsive
genes in breast cancer cells
The majority of breast cancers express ERa, and the growth
of ERa-positive breast tumours is stimulated by estrogen,
as evidenced by the utility of anti-estrogens and inhibitors
of estrogen biosynthesis in breast cancer treatment (2). The
MCF7 breast cancer cell line expresses ERa and grows in
response to estrogen, its growth being inhibited by
anti-estrogens. Further, MCF7 cells demonstrate estrogen-
stimulated expression of a number of well-characterized
estrogen-responsive genes, including cathepsin D and pS2.
In order to evaluate the effect of ZNF366 on ERa-regulation
Figure 4. ZNF366 is a repressor of ERa activity. (A) COS-1 cells were transfected with ERE-3-TATA-luc (100 ng), ERa (100 ng), ZNF366 and the RLTK
renilla luciferase reporter (100 ng). Results represent the mean of three independent experiments individually corrected for transfection efficiency against renilla
luciferase activity. Error bars represent the standard error of the mean. The activity for ERa in the presence of E2 and in the absence of ZNF366 was taken as
100%. All other activities are shown relative to this. The amounts of ZNF366 transfected were 0 ng (lanes 1, 7, 13 and 19), 0.1 ng (lanes 2, 8, 14 and 20), 1 ng
(lanes 3, 9, 15 and 21), 10 ng (lanes 4, 10, 16 and 22), 30 ng (lanes 5, 11, 17 and 23) or 100 ng (lanes 6, 12, 18 and 24). (B and C) Reporter gene assays were
performed following transfection of 100 ng ERaDLBD (B) or ERaDAF1 (C), as for (A). (D) COS-1 cells were co-transfected with 100 ng Gal4 DBD,
the Gal4 DBD fused to full-length RIP140 or ZNF366 together with LexA-VP16 and the Lex-Gal-luc reporter gene. Relative reporter gene activities from three
independent experiments are shown. (E) Shown are RT–PCR carried out using PCR primers for GREB1, TERT, ZNF366, Lamin A/C and GAPDH, using total
RNA prepared from PE04 cells transfected with non-targeting control, Lamin A/C, or ZNF366 siRNA.
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of these genomically encoded estrogen-responsive genes,
MCF7 cells were transfected with ZNF366. This resulted
in a marked reduction in expression of both cathepsin
D and pS2 (Figure 7A). MCF7 cell growth was also reduced
following ZNF366 transfection (Figure 7B), whilst growth of
an ERa-negative breast cancer cell line that is not estrogen-
responsive, was not inhibited by ZNF366 (Figure 7C).
DISCUSSION
Zinc finger proteins constitute a very large family of trans-
criptional regulators and can be further subdivided into
groupings based on the type of zinc finger present, as well
as by the presence of additional motifs elsewhere in the
protein that mediate protein–protein interactions and tran-
scriptional regulation. Sequence analysis of ZNF366 shows
that it encodes encodes a protein containing 11 Kruppel-
type C2H2 zinc fingers, which is highly conserved in verte-
brate evolution. However, ZNF366 does not belong to any
of the major subfamilies of the Kruppel zinc finger family
and shows most significant amino acid sequence similarity
to one other Kruppel zinc finger protein, ZNF710, of
unknown function, where the homology is restricted to the
Kruppel zinc finger region. However, several other Kruppel-
type zinc finger proteins act as transcriptional repressors,
including ZNF217, a putative oncogene that is amplified
and overexpressed in breast and other cancers (55,56), and
Figure 5. ZNF366 interacts with CtBP in vitro and in vivo. RIP140 fragments (A), ZNF366 fragments (B), CtBP1 (A and E) or ERaDLBD (A) fused to GST,
were immobilized on glutathione beads and incubated with 35S-labelled ZNF366 (A and C), CtBP1 (A, B) or RIP140 (B). Bound proteins were eluted, resolved
by 10% SDS–PAGE and exposed to autoradiography. (D) Mammalian 2-hybrid assay was performed by co-transfecting 100 ng Gal4 DBD or Gal4 fusions with
ZNF366 558–744 amino acids, and 100 ng of VP16 or VP16 fused to CtBP. (E) COS-1 cells were co-transfected with LexA-VP16 and the Lex-Gal-luc reporter
plasmid, together with the Gal4 DBD or Gal4 fused to 558–744 amino acids of ZNF366 in which the N-terminal (M1), the C-terminal (M2) or both (M1/M2)
CtBP binding motifs have been mutated. Relative reporter gene activities from three independent experiments are shown. (F and G) Whole cell lysates prepared
from COS-1 cells transiently transfected with CtBP1 and FLAG-tagged ZNF366 or FLAG-tagged ZNF366 mutated in the CtBP binding sites were
immunoprecipitated using antibodies to CtBP1, followed by western blotting for CtBP1 and FLAG (F) or using the FLAG antibody followed by western blotting
for FLAG and CtBP1 (G). In each case control immunoprecipitations were performed using mouse IgG.
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copurifies with a CtBP corepressor complex (42). Further, the
Bcl11 Kruppel zinc finger gene, which is translocated in
B-cell chronic lymphocytic leukemias, acts as a corepressor
for the COUP-TF NR (57).
Although we did not investigate the potential of ZNF366 to
bind DNA, alter reporter gene activities in yeast or in mam-
malian cells in the absence of ERa (see Results and Supple-
mentary Figure 1A). Further, ZNF366 did not bind to
estrogen response elements in gelshift assays (Supplementary
Figure 1B). Recruitment of ERa to the estrogen-responsive
pS2 gene promoter was also not inhibited by ZNF366 expres-
sion in MCF7 cells (Supplementary Figure 1C). Collectively,
these findings indicate that the repression of estrogen-
responsive reporter genes by ZNF366 does not involve
inhibition of DNA binding by ERa.
ZNF366 appears to be recruited to estrogen-responsive
genes through interaction of the zinc finger region of
ZNF366 with the zinc finger region (DBD) of ERa. Whilst
the zinc finger region was required for ZNF366 interaction
with ERa, the exact sequence requirements for the interaction
with ERa were not established, although non-overlapping
regions of ZNF366, encoding zinc fingers 1–7 or 8–11 were
sufficient for the interaction. Whilst the interaction of
ZNF366 and ERa did not require ligand for in vitro assays,
the interaction was apparently better in the presence of estro-
gen. Further, in vivo assays demonstrated a requirement for
estrogen or anti-estrogen binding for the interaction between
ZNF366 and ERa. The in vivo requirement for ligand binding
may be influenced by post-translational modifications. Addi-
tionally, steroid receptors, including ERa, are complexed in
the unliganded state, with the Hsp90 chaperone complex,
required for appropriate folding of steroid receptors (58).
The Hsp90-steroid receptor also likely interferes with steroid
receptor interaction with some proteins. Ligand binding
results in a conformational change in steroid receptors and
Hsp90 dissociation. This could explain the estrogen and
anti-estrogen regulation of ZNF366 recruitment by ERa.
In vitro, ZNF366 also interacted with other steroid recep-
tors (ERb, androgen and glucocorticoid receptors), as well
as the non-steroid retinoic acid, retinoid X and peroxisome
proliferators-activated receptors (data not shown). In all
cases the ZNF366 zinc finger region mediated the interaction,
with no interaction being detected for the region C-terminal
to the zinc finger region (558–744 amino acids), with
the exception of retinoid X receptor-a (RXRa). In this
case, ligand-stimulated interaction of RXRa with 558–744
amino acids was observed, indicating that the interaction
between ZNF366 and RXRa is mechanistically distinct
from the interaction of ZNF366 with other NRs, perhaps
requiring the potential LXXLL motif located near the
C-terminus of ZNF366.
ZNF366 inhibited ligand-dependent transactivation by
ERa in a dose-dependent manner and functioned as a repres-
sor when tethered to DNA by the GAL4 DBD. Its interaction
with the ERa DBD suggests that the observed repression is
not due simply to prevention of coactivator recruitment, nor
does ZNF366 inhibit DNA binding by ERa (data not
shown). Rather, ZNF366 appears to recruit multiple factors
that act to repress transcription. Hence, the HDAC inhibitor
SAHA partially relieved the repression of ERa by ZNF366
and in vitro binding assays showed that ZNF366 interacts
with Class I HDACs 1 and 3, as well as the Class II
HDAC6, indicating that the corepressor activity of ZNF366
is, at least in part, HDAC-dependent.
Figure 6. Repression of ERa activity by ZNF366 involves HDACs. (A) COS-1
cells were transfected with ERE-3-TATA-luc (100 ng), ERa (100 ng) and
ZNF366 (10 ng) or ZNF366 in which the CtBP sites have been mutated
(ZNF366-Mut). E2 (10 nM) was present throughout. Results represent the
mean of three independent experiments. (B) SAHA and E2 were added 24 h
following transfection with ERa and ZNF366 and cells processed as above.
GST pulldowns were carried out by incubation of 35S-labelled HDAC 1, 3, 4 or
6, with GST-ZNF366 fusion proteins. The input lanes represent 20% of the
total volume of the in vitro translation reaction used in the binding assay.
Figure 7. ZNF366 acts as a corepressor for endogenous estrogen-responsive
genes. (A) MCF7 cells cultured in estrogen-free medium for 3 days were
transfected with ZNF366 or control vector. E2 (10 nM) was added 24 h
following transfection and lysates prepared after a further 24 h, were
immunoblotted for cathepsin D (CTD), pS2, FLAG-ZNF366 and b-actin.
(B and C) MCF7 and MDA-MB-231 cells were transfected as above and cell
counts obtained 72 h after the addition of E2. The means of three experiments
are shown, error bars representing the standard error of the mean.
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Several different corepressor complexes that are associated
with NRs have been identified, most notably N-CoR–SMRT
complexes that include HDACs (59). These are usually
recruited to unliganded or antagonist-bound NRs, such as
the tamoxifen-bound ERa (60). RIP140 is unusual in being
a corepressor that is recruited by agonist-bound NRs. The
repressive activity of RIP140 is achieved by the recruitment
of class I HDACs and CtBP1 (35–39,61). CtBP1 and the
related protein CtBP2 are potent corepressors that are present
in protein complexes containing HDACs and histone lysine
methyltransferases (42), and its corepressor activity is
mediated through HDAC-dependent and—independent
mechanisms, the HDAC-independent mechanisms likely
involving PcG complexes (62). ZNF366 interacted with
RIP140, the interaction requiring 455–558 amino acids of
ZNF366, which encode zinc fingers 7–11. ZNF366 also
interacted with CtBP1 in vitro and in vivo, the interaction
being mediated by two PXDLS CtBP-interaction motifs
located C-terminal to the zinc fingers in ZNF366. Mutation
of the CtBP-interacting motifs prevented the interaction of
ZNF366 and CtBP1 and relieved repression of ERa activity
by ZNF366, confirming the importance of CtBP recruitment
for the corepressor activity of ZNF366. However, the mutant
ZNF366 still significantly repressed ERa activity, likely due
to the fact that it directly interacts with HDACs and with
RIP140.
These studies suggest that ZNF366 acts as a corepressor
for ERa. In agreement with these findings, transfection of
ZNF366 into the estrogen-responsive and ERa-positive
MCF7 breast cancer cell line, which does not express
ZNF366 (data not shown), reduced expression of genomically
encoded ERa-regulated genes. Moreover, expression of
ZNF366 inhibited MCF7 cell growth in response to estrogen,
whereas ZNF366 expression did not inhibit growth of the
ERa-negative, MDA-MB-231 breast cancer cell line that is
not estrogen-responsive. Finally, RNAi-mediated down-
regulation of ZNF366 in the ERa-positive PE04 ovarian
cell line, stimulated expression of the estrogen-regulated
GREB1 and TERT genes, further evidence for the in vivo
role of ZNF366 as a corepressor for ERa.
In summary, we have identified a novel ERa-interacting
protein ZNF366, which represses ligand-dependent ERa
transactivation by recruitment of multiple factors, to regulate
the expression of estrogen-responsive genes. ZNF366 is
widely expressed in adult tissues and our preliminary findings
of interaction between ZNF366 and many other NRs suggest
that ZNF366 may have a widespread role as a NR corepres-
sor, in addition to its action as an ERa corepressor, as defined
in this study.
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